U.S., EU clear manufacturing plant for Bavarian Nordic's monkeypox vaccine

FILE PHOTO: An employee of the vaccine company Bavarian Nordic works in a laboratory of the company in Martinsried near Munich, Germany, May 24, 2022. REUTERS/Lukas Barth/File Photo

(Reuters) -Drugmaker Bavarian Nordic said U.S. and European regulators have approved the use of Jynneos vaccine doses made at the company's plant in Denmark as global efforts to tackle the monkeypox outbreak pick up pace.

The U.S. Food and Drug Administration's approval for the fill-and-finish plant will lead to the availability of an additional 786,000 doses of vaccine in the United States, Health and Human Services Secretary Xavier Becerra said in a statement. (https://bit.ly/3PGKZRj)